| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000100 | 2019-02-26 | ||
| PCT/EP2020/054821WO2020173897A1 (en) | 2019-02-26 | 2020-02-25 | Novel fusion proteins specific for cd137 and gpc3 |
| Publication Number | Publication Date |
|---|---|
| SG11202106353VAtrue SG11202106353VA (en) | 2021-07-29 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106353VASG11202106353VA (en) | 2019-02-26 | 2020-02-25 | Novel fusion proteins specific for cd137 and gpc3 |
| Country | Link |
|---|---|
| US (1) | US20220153864A1 (en) |
| EP (1) | EP3931209A1 (en) |
| JP (1) | JP7476219B2 (en) |
| KR (1) | KR20210133254A (en) |
| CN (1) | CN113474359B (en) |
| AU (1) | AU2020229436B2 (en) |
| BR (1) | BR112021016829A2 (en) |
| CA (1) | CA3124441A1 (en) |
| IL (1) | IL284687A (en) |
| MA (1) | MA55069A (en) |
| MX (1) | MX2021010039A (en) |
| SG (1) | SG11202106353VA (en) |
| WO (1) | WO2020173897A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020201038A1 (en)* | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CN118103063A (en)* | 2021-04-05 | 2024-05-28 | 赛托维亚治疗有限责任公司 | Bispecific antibodies targeting NKp46 and GPC3 and methods of use thereof |
| JP2024515202A (en)* | 2021-04-23 | 2024-04-05 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-GPC3 antibodies, multispecific antibodies and methods of use |
| EP4341294A1 (en)* | 2021-05-21 | 2024-03-27 | BeiGene Switzerland GmbH | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use |
| AU2022326107A1 (en) | 2021-08-12 | 2024-03-14 | Shanghai Ttm-Bio Technology Co., Ltd. | Bispecific recombinant protein and use thereof |
| CN115960242B (en)* | 2021-09-09 | 2023-10-17 | 广东东阳光药业股份有限公司 | Anticancer binding molecules and uses thereof |
| CN113912699A (en)* | 2021-10-14 | 2022-01-11 | 江南大学 | Novel FGF analogue for treating breast cancer and application thereof |
| CN113956344A (en)* | 2021-10-14 | 2022-01-21 | 江南大学 | Novel FGF analogue for treating liver cancer and application thereof |
| CN116640224A (en)* | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Fusion protein of CD137 antibody and CD40L and application thereof |
| EP4494659A1 (en)* | 2022-03-18 | 2025-01-22 | Duality Biologics (Suzhou) Co., Ltd. | Anti-gpc3 antibody drug conjugate and use thereof |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (en) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | Production of normal human serum albumin a through gene recombination |
| FR2649991B2 (en) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| ES2241710T3 (en) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN. |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| ATE307597T1 (en) | 1998-06-08 | 2005-11-15 | Hoffmann La Roche | USE OF PEG-IFN-ALPHA AND RIBAVIRIN TO TREAT CHRONIC HEPATITIS C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| MX2009001203A (en)* | 2006-08-01 | 2009-06-01 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same. |
| EP2617736A1 (en)* | 2007-09-28 | 2013-07-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having improved kinetics in plasma |
| KR101527297B1 (en)* | 2010-09-09 | 2015-06-26 | 화이자 인코포레이티드 | 4-1bb binding molecules |
| WO2013174783A1 (en)* | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP2911691B1 (en)* | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| MA40764A (en)* | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
| KR20170138574A (en)* | 2015-05-04 | 2017-12-15 | 피어이스 파마슈티컬즈 게엠베하 | Anticancer fusion polypeptide |
| AU2016258952C1 (en)* | 2015-05-04 | 2020-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| US10273275B2 (en)* | 2015-05-18 | 2019-04-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof |
| WO2016184882A1 (en)* | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| WO2018087108A1 (en)* | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| RU2019124709A (en)* | 2017-01-06 | 2021-02-08 | Момента Фармасьютикалз, Инк. | COMPOSITIONS AND METHODS ASSOCIATED WITH DESIGNED CONSTRUCTIONS BASED ON Fc-ANTIGEN BINDING DOMAIN |
| CN110719920B (en)* | 2017-06-14 | 2024-01-30 | 苏州丁孚靶点生物技术有限公司 | Protein heterodimers and uses thereof |
| Publication number | Publication date |
|---|---|
| EP3931209A1 (en) | 2022-01-05 |
| IL284687A (en) | 2021-08-31 |
| MX2021010039A (en) | 2021-09-21 |
| WO2020173897A1 (en) | 2020-09-03 |
| CN113474359B (en) | 2025-02-21 |
| CN113474359A (en) | 2021-10-01 |
| US20220153864A1 (en) | 2022-05-19 |
| JP7476219B2 (en) | 2024-04-30 |
| BR112021016829A2 (en) | 2021-10-19 |
| AU2020229436B2 (en) | 2024-12-19 |
| MA55069A (en) | 2022-01-05 |
| KR20210133254A (en) | 2021-11-05 |
| JP2022523524A (en) | 2022-04-25 |
| CA3124441A1 (en) | 2020-09-03 |
| AU2020229436A1 (en) | 2021-07-01 |
| Publication | Publication Date | Title |
|---|---|---|
| IL284687A (en) | Novel fusion proteins specific for cd137 and gpc3 | |
| ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| IL273439A (en) | Fusion proteins comprising enzyme replacement therapy enzymes | |
| IL279510A (en) | Progranulin-fc polypeptide fusion proteins and uses thereof | |
| IL276469A (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
| EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
| IL289887A (en) | Fusion polypeptide for immunotherapy | |
| EP3275895A4 (en) | Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| IL287318A (en) | Materials and methods for protein production | |
| IL290675A (en) | Therapeutic fusion proteins | |
| SG11202000775SA (en) | Fusion tags for recombinant protein expression | |
| IL304317A (en) | Tgf-beta-rii binding proteins | |
| ZA202102533B (en) | Fusion protein | |
| IL290715A (en) | Nkg2d fusion proteins and uses thereof | |
| GB201919294D0 (en) | Antibodies or binding proteins | |
| IL287928A (en) | Variant domains for multimerizing proteins and separation thereof | |
| IL286419A (en) | Novel selection marker-comprising cell line and uses thereof for protein production | |
| GB202105044D0 (en) | Fusion protein | |
| PT3830120T (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| GB201919461D0 (en) | Protein separation | |
| IL319272A (en) | Novel fusion protein specific for cd137 and cd228 | |
| GB201913320D0 (en) | Novel proteins | |
| GB201919286D0 (en) | Binding proteins | |
| GB201904756D0 (en) | Novel proteins |